Aileron Therapeutics’ (NASDAQ:ALRN) lock-up period is set to end on Tuesday, December 26th. Aileron Therapeutics had issued 3,750,000 shares in its initial public offering on June 29th. The total size of the offering was $56,250,000 based on an initial share price of $15.00. After the expiration of Aileron Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Aileron Therapeutics (NASDAQ:ALRN) opened at $9.83 on Thursday. Aileron Therapeutics has a one year low of $9.25 and a one year high of $15.48.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALRN. Jennison Associates LLC bought a new position in shares of Aileron Therapeutics during the second quarter valued at approximately $2,788,000. Sphera Funds Management LTD. bought a new position in shares of Aileron Therapeutics during the second quarter valued at approximately $1,394,000. Nexthera Capital LP bought a new position in shares of Aileron Therapeutics during the second quarter valued at approximately $1,272,000. Goldman Sachs Group Inc. bought a new position in shares of Aileron Therapeutics during the second quarter valued at approximately $418,000. Finally, Laurion Capital Management LP bought a new position in shares of Aileron Therapeutics during the second quarter valued at approximately $335,000. Hedge funds and other institutional investors own 7.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/aileron-therapeutics-incs-lock-up-period-to-end-on-december-26th-nasdaqalrn/1775253.html.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.